Warning Letter — Wizcure Pharmaa Private Limited
The FDA issued a Warning Letter to Wizcure Pharmaa Private Limited following an assessment by the Center for Drug Evaluation and Research (CDER).
This action specifically affects Wizcure Pharmaa Private Limited and its internal departments responsible for pharmaceutical manufacturing, quality control, and regulatory compliance.
The issuance of a Warning Letter by CDER signifies that the FDA has identified significant violations of Current Good Manufacturing Practice (CGMP) or other regulatory requirements. While the specific violations are not detailed in the brief excerpt, such letters typically indicate that the firm's responses to previous inspectional observations were insufficient, potentially leading to import alerts or restricted distribution if not remediated.
Facilities should conduct a rigorous internal audit of current manufacturing processes against CGMP standards and ensure all facility registrations and drug listings are current with the FDA to avoid import or distribution disruptions.
FDA Warning Letter issued to: Wizcure Pharmaa Private Limited. 06/24/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wizcure-pharmaa-private-limited-726378-06242026
Open in openFDA / FDA.gov